Wednesday, January 20, 2021
Home > Deal

Merck Seals $425M Buyout Deal with OncoImmune for COVID-19 Drug

The deal with OncoImmune will see Merck take up the ownership of CD24Fc with additional payment made to OncoImmune based on future favorable regulatory approvals associated with the drug.American multinational pharmaceutical company Merck & Co Inc (NYSE: MRK) has inked a $425 million deal with OncoImmune, a privately-held, clinical-stage biopharmaceutical

Read More